Cargando…
Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(−2), 5-fluorouracil 500 mg m(−2), epidoxorubicin 35 mg m(−2), 6S stereoisomer of leucovorin 250 mg m(−2) and glutathione 1.5 mg m(−2), supported by a da...
Autores principales: | Cascinu, S, Frontini, L, Comella, G, Barni, S, Labianca, R, Battelli, N, Casaretti, R, Zonato, S, Pirovano, M, Catalano, G, Cellerino, R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362406/ https://www.ncbi.nlm.nih.gov/pubmed/10027318 http://dx.doi.org/10.1038/sj.bjc.6690076 |
Ejemplares similares
-
Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
por: Cascinu, S., et al.
Publicado: (1998) -
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
por: Cascinu, S, et al.
Publicado: (1999) -
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer
por: Cascinu, S, et al.
Publicado: (2001) -
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
por: Cascinu, S, et al.
Publicado: (2004) -
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial
por: Giampieri, Riccardo, et al.
Publicado: (2017)